Abstract
Tardive dyskinesia (TD) is a severe, debilitating movement disorder observed in 25–30% of the patients treated with typical antipsychotics. Cannabinoid receptor 1 (CNR1) activators tend to inhibit movement, an effect prevented by rimonabant and other selective CNR1 antagonists. Furthermore, CNR1 receptor is downregulated in Huntington's disease and upregulated in Parkinson's disease. Twenty tagSNPs spanning the CNR1 gene were analyzed in schizophrenia patients of European ancestry (n=191; 74 with TD). Significant genotypic (P=0.012) and allelic (P=0.012) association was observed with rs806374 (T>C). Carriers of the CC genotype were more likely to be TD positive (CC vs TT+TC, odds ratio=3.4 (1.5–7.8), P=0.003) and had more severe TD (CC vs TT+TC; 9.52±9.2 vs 5.62±6.9, P=0.046). These results indicate a possible role of CNR1 in the development of TD in our patient population. However, these observations are marginal after correcting for multiple testing and need to be replicated in a larger patient population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Casey DE . Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109–120.
Leucht S, Wahlbeck K, Hamann J, Kissling W . New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–1589.
Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279–288.
Correll CU, Schenk EM . Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151–156.
Tarsy D, Baldessarini RJ . Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589–598.
Gerlach J . Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14: 47–57.
Marsalek M . Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33 (Suppl 1): 14–33.
Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375–379.
Muller DJ, Shinkai T, De Luca V, Kennedy JL . Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4: 77–87.
Thelma B, Srivastava V, Tiwari AK . Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9: 1285–1306.
Katona I, Freund TF . Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008; 14: 923–930.
Hudson BD, Hebert TE, Kelly ME . Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 2010; 77: 1–9.
van der Stelt M, Di Marzo V . The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003; 480: 133–150.
Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF . Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2006; 137: 337–361.
Fernandez-Ruiz J . The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009; 156: 1029–1040.
Albin RL, Young AB, Penney JB . The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366–375.
Surmeier DJ, Ding J, Day M, Wang Z, Shen W . D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007; 30: 228–235.
Kreitzer AC, Malenka RC . Striatal plasticity and basal ganglia circuit function. Neuron 2008; 60: 543–554.
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI . Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780–5785.
Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008; 33: 1667–1679.
Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M . Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998; 5 (6 Part B): 483–501.
Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D . Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2: 358–363.
Kreitzer AC, Malenka RC . Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007; 445: 643–647.
Shen W, Flajolet M, Greengard P, Surmeier DJ . Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008; 321: 848–851.
Zai CC, Hwang RW, De Luca V, Muller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639–651.
Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Muller DJ et al. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res 2008; 106: 248–252.
Zai CC, Tiwari AK, De Luca V, Muller DJ, Bulgin N, Hwang R et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009; 19: 317–328.
Zai CC, Tiwari AK, Basile V, de Luca V, Muller DJ, Voineskos AN et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 50–56.
Guy W . ECDEU Assessment Manual for Psychopharmacology (revised edn.) Department of Health, Education and Welfare: Washington, DC, 1976.
Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486–487.
Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17–27.
Lieberman J, Kane JM, Woerner M, Weinhold P, Basavaraju N, Kurucz J et al. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984; 20: 382–386.
Lieberman J, Johns C, Cooper T, Pollack S, Kane J . Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99 (Suppl): S54–S59.
Lahiri DK, Nurnberger Jr JI . A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
Dudbridge F . Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115–121.
Barrett JC, Fry B, Maller J, Daly MJ . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.
Gauderman WJ, Morrison JM . QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe, 2006.
Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 2010; 35: 1315–1324.
Nyholt DR . A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765–769.
Li J, Ji L . Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95: 221–227.
Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004; 9: 916–931.
Pabst O, Forster R, Lipp M, Engel H, Arnold HH . NKX2.3 is required for MAdCAM-1 expression and homing of lymphocytes in spleen and mucosa-associated lymphoid tissue. EMBO J 2000; 19: 2015–2023.
Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40: 710–712.
Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40: 713–715.
Van Limbergen J, Wilson DC, Satsangi J . The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009; 10: 89–116.
Andersen B, Schonemann MD, Pearse II RV, Jenne K, Sugarman J, Rosenfeld MG . Brn-5 is a divergent POU domain factor highly expressed in layer IV of the neocortex. J Biol Chem 1993; 268: 23390–23398.
Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 2010; 107: 1100–1105.
Acknowledgements
Canadian Institutes of Health Research (CIHR) operating grants to JLK and DJM; a NARSAD Young Investigator Award to DJM, MH41468, the Prentiss Foundation, Ritter Foundation, Hintz family and the Peterson Family to HYM; The Bebensee Foundation fellowship to CCZ and CIHR postdoctoral fellowship to AKT.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
AKT/CCZ/DJM: report no competing interests. HYM has received grants or is a consultant to Abbott Labs, ACADIA, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Astra Zeneca, Glaxo Smith Kline, Memory, Cephalon, Minster, Aryx and BiolineRx. HYM is a shareholder of ACADIA. JAL reports that he serves on the Advisory Board of Bioline, GlaxoSmithKline, Intracellular Therapies, Eli Lilly, Pierre Fabre, Psychogenics and Wyeth. He does not receive financial compensation or salary support for his participation as an advisor. He receives grant support from Allon, Forest Labs, Merck and Pfizer; he holds a patent from Repligen. JLK has been a consultant to GSK, Sanofi-Aventis and Dainippon-Sumitomo.
Additional information
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tiwari, A., Zai, C., Likhodi, O. et al. Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J 12, 260–266 (2012). https://doi.org/10.1038/tpj.2010.93
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2010.93
Keywords
This article is cited by
-
Genome wide study of tardive dyskinesia in schizophrenia
Translational Psychiatry (2021)